Advertisement

Molecular Detection of Occult Tumor Cells

  • Karen L. Kaul
Chapter
  • 1.7k Downloads

Abstract

One of the key roles performed by pathologists is determination of the presence or absence of tumor cells in clinical samples. This is the basis for most approaches to staging, monitoring response to treatment, and detecting relapse of neoplasia and, as such, is a critical step in determining the course of patient management. Pathologists have utilized a variety of approaches, continually seeking to improve performance and thus patient outcome. The literature reflects this quest, including reports assessing the increased sensitivity afforded by step sectioning, immunohistochemistry, flow cytometry, and, more recently, molecular approaches for the detection of tumor cells in blood, bone marrow, and lymph node samples. The goal is, of course, the more accurate detection of disease spread and, ultimately, better patient care.

Keywords

Breast Cancer Clin Oncol Radical Prostatectomy Circulate Tumor Cell Molecular Detection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ghossein RA, Bhattacharya S, Coit DG. Reverse transcriptase polymerase chain reaction (RT-PCR) detection of melanoma-related transcripts in the peripheral blood and bone marrow of patients with malignant melanoma. What have we learned? Cancer Res. 2001;158:63–77.Google Scholar
  2. 2.
    Pantel K, Cote RJ, Fodstad O. Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst. 1999;91:1113–1124.PubMedCrossRefGoogle Scholar
  3. 3.
    Raj GV, Moreno JG, Gomela LG. Utilization of polymerase chain reaction technology in the detection of solid tumors. Cancer. 1998;82:1419–1442.PubMedCrossRefGoogle Scholar
  4. 4.
    Vogel I, Kalthoff H. Disseminated tumour cells. Their detection and significance for prognosis of gastrointestinal and pancreatic carcinomas. Virchows Arch. 2001;439:109–117.PubMedCrossRefGoogle Scholar
  5. 5.
    Calaluce R, Miedema BW, Yohannes WY. Micrometastases in colorectal carcinoma: a review. J Surg Oncol. 1998;67:194–202.PubMedCrossRefGoogle Scholar
  6. 6.
    Zippelius A, Pantel K. RT-PCR-based detection of occult disseminated tumor cells in peripheral blood and bone marrow of patients with solid tumors. An overview. AnnNYAcad Sci. 2000;906:110–123.CrossRefGoogle Scholar
  7. 7.
    Bauer KD, de la Torre-Bueno J, Diel IJ, et al. Reliable and sensitive analysis of occult bone marrow metastases using automated cellular imaging. Clin Cancer Res. 2000;6:3552–3559.PubMedGoogle Scholar
  8. 8.
    Tvasellas G, Huang A, McCullough T, Patel H, Araia R, Allen-March TG. Flow cytometry correlates with RT-PCR for detection of spiked but not circulating colorectal cancer cells. Clin Exp Metastasis. 2002;19:495–502.CrossRefGoogle Scholar
  9. 9.
    Barr FG, Ladanyi M. Sarcomas. In: Leonard DGB, ed. DiagnosticMolecular Pathology: Major Problems in Pathology. Vol 41. Philadelphia: WB Saunders Co; 2003:53–76.Google Scholar
  10. 10.
    Kimura W, Zhao B, Futakawa N, et al. Significance of Ki-ras codon 12 point mutation in pancreatic juice in diagnosis of carcinoma of the pancreas. Hepatogastroenterology. 1999;46:532–539.PubMedGoogle Scholar
  11. 11.
    Wenger FA, Zieren J, Peter FJ, et al. K-ras mutations in tissue and stool samples from patients with pancreatic cancer and chronic pancreatitis. Langenbecks Arch Surg. 1999;384:181–186.PubMedCrossRefGoogle Scholar
  12. 12.
    Uehara H, Nakaizumi A, Baba M, et al. Diagnosis of pancreatic cancer by K-ras point mutation and cytology of pancreatic juice. Am J Gastroenterol. 1996;91:1616–1621.PubMedGoogle Scholar
  13. 13.
    Mao L, Schoenberg MP, Scicchitano M, et al. Molecular detection of primary bladder cancer by microsatellite analysis. Science. 1996;271:659–662.PubMedCrossRefGoogle Scholar
  14. 14.
    Nawroz H, Koch W, Anker P, Stroun M, Sidransky D. Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med. 1996;2:1035–1037.PubMedCrossRefGoogle Scholar
  15. 15.
    Luke S, Kaul K. Detection of breast cancer cells in blood using immunomagnetic bead selection and reverse transcription-polymerase chain reaction. Mol Diagn. 1998;3:149–155.PubMedCrossRefGoogle Scholar
  16. 16.
    Naume B, Borgen E, Nesland JM, et al. Increased sensitivity for detection of micrometastases in bone marrow/peripheral blood stem-cell products from breast-cancer patients by negative immunomagnetic separation. Int J Cancer. 1998;78:556–560.PubMedCrossRefGoogle Scholar
  17. 17.
    Burchill SA, Perebolte L, Johnston C, Top B, Selby P. Comparison of the RNA-amplification based methods RT-PCR and NASBA for the detection of circulating tumour cells. Br J Cancer. 2002;86:102–109.PubMedCrossRefGoogle Scholar
  18. 18.
    Silva JM, Garcia JM, Dominguez G, et al. Persistence of tumor DNA in plasma of breast cancer patients after mastectomy. Ann Surg Oncol. 2002;9:71–76.PubMedCrossRefGoogle Scholar
  19. 19.
    Silva JM, Rodriguez R, Garcia JM, et al. Detection of epithelial tumour RNA in the plasma of colon cancer patients is associated with advanced stages and circulating tumour cells. Gut. 2002;50:530–534.PubMedCrossRefGoogle Scholar
  20. 20.
    Gocke CD, Kopreski MS, Evans D. Telomerase mRNA is detectable in the plasma of pancreatic cancer patients [abstract]. Clin Chem. 2001;47:369.Google Scholar
  21. 21.
    Traweek ST, Liu J, Battifora H. Keratin gene expression in non-epithelial tissues. Detection with polymerase chain reaction. Am J Pathol. 1993;142:1111–1118.PubMedGoogle Scholar
  22. 22.
    Lambrechts AC, Bosma AJ, Klaver SG, et al. Comparison of immunohistochemistry, reverse transcriptase polymerase chain reaction, and nucleic acid sequence-bases amplification for the detection of circulating breast cancer cells. Breast Cancer Res Treat. 1999;56:219–231.PubMedCrossRefGoogle Scholar
  23. 23.
    Mitas M, Mikhitarian K, Walters C, et al. Quantitative real-time RT-PCR detection of breast cancer micrometastasis using a multigene marker panel. Int J Cancer. 2001;93:162–171.PubMedCrossRefGoogle Scholar
  24. 24.
    Taback B, Chan AD, Kuo CT, et al. Detection of occult metastatic breast cancer cells in blood by a multimolecular marker assay: correlation with clinical stage of disease. Cancer Res. 2001;61:8845–8850.PubMedGoogle Scholar
  25. 25.
    Hu X-C, Chow LWC. Detection of circulating breast cancer cells with multiple-marker RT-PCR assay. Anticancer Res. 2001;21:421–424.PubMedGoogle Scholar
  26. 26.
    Slade MJ, Smith BM, Sinnett HD, Cross NC, Coombes RC. Quantitative polymerase chain reaction for the detection of micrometastases in patients with breast cancer. J Clin Oncol. 1999;17:780–789.Google Scholar
  27. 27.
    Bostick P, Chatergee S, Chi D, et al. Limitations of RT-PCR in the detection of micrometastases in the lymph nodes of breast cancer patients. J Clin Oncol. 1998;16:2632–2640.PubMedGoogle Scholar
  28. 28.
    Christofanilli M, Hayes DF, Budd GT, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781–791.CrossRefGoogle Scholar
  29. 29.
    Schoenfeld A, Luqmani Y, Smith D, et al. Detection of breast cancer micrometastases in axillary lymph nodes by using polymerase chain reaction. Cancer Res. 1994;54:2986–2990.PubMedGoogle Scholar
  30. 30.
    Braun S, Pantel K, Müller P, et al. Cytokeratin-positive cells in the bone marrow and survival or patients with stage I, II, or III breast cancer. N Engl J Med. 2000;342:525–533.PubMedCrossRefGoogle Scholar
  31. 31.
    Schoenfeld A, Kruger KH, Gomm J, et al. The detection of micrometastases in the peripheral blood and bone marrow if patients with breast cancer using immunohistochemistry and reverse polymerase chain reaction for keratin 19. Eur J Cancer. 1997;33:845–861.CrossRefGoogle Scholar
  32. 32.
    Katz AE, de Vries GM, Begg MD, et al. Enhanced reverse transcriptase-polymerase chain reaction for prostate specific antigen as an indicator of true pathologic stage in patients with prostate cancer. Cancer. 1995;75:1642–1648.PubMedCrossRefGoogle Scholar
  33. 33.
    Ignatoff JM, Oefelein MG, Watkin W, Chmiel JS, Kaul KL. Prostate specific antigen (PSA) reverse transcriptase polymerase chain reaction (RT-PCR) assay in preoperative staging of prostate cancer. J Urol. 1997;158:1870–1875.PubMedCrossRefGoogle Scholar
  34. 34.
    Shariat SF, Gottenger E, Nguyen C, et al. Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy. Cancer Res. 2002;62:5974–5979.PubMedGoogle Scholar
  35. 35.
    Bianco FJ Jr, Powell IJ, Cher ML, Wood DP Jr. Presence of circulating prostate cancer cells in African American males adversely affects survival. Urol Oncol. 2002;7:147–152.PubMedCrossRefGoogle Scholar
  36. 36.
    Su SL, Heston WD, Perrotti M, et al. Evaluating neoadjuvant therapy effectiveness on systemic disease: use of a prostatic-specific membrane reverse transcription polymerase chain reaction. Urology. 1997;49:95–101.PubMedCrossRefGoogle Scholar
  37. 37.
    Shariat SF, Roudier MP, Wilcox GE, et al. Comparison of immunohistochemistry with reverse transcription-PCR for the detection of micrometastatic prostate cancer in lymph nodes. Cancer Res. 2003;63:4662–4670.PubMedGoogle Scholar
  38. 38.
    Shariat SF, Kattan MW, Erdamar S, et al. Detection of clinically significant, occult prostate cancer metastases in lymph nodes using a splice variant-specific rt-PCR assay for human glandular kallikrein. J Clin Oncol. 2003;21:1223–1231.PubMedCrossRefGoogle Scholar
  39. 39.
    Wood DP Jr, Banerjee M. Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease-free survival. J Clin Oncol. 1997;15:3451–3457.PubMedGoogle Scholar
  40. 40.
    Soeth E, Roder C, Juhl H, Kruger U, Kremer B, Kalthoff H. The detection of disseminated tumor cells in bone marrow from colorectal cancer patients by a cytokeratin 20 specific nested reverse transcriptase-polymerase chain reaction is related to the stage of disease. Int J Cancer. 1996;69:278–282.PubMedCrossRefGoogle Scholar
  41. 41.
    Liefers GJ, Cleton-Jansen AM, van de Velde CJH, Hermans J, van Krieken JH, Cornelisse CJ. Micrometastases and survival in stage II colorectal cancer. N Engl J Med. 1998;339:223–228.PubMedCrossRefGoogle Scholar
  42. 42.
    Rosenberg R, Hoos A, Mueller J, et al. Prognostic significance of cytokeratin-20 reverse transcriptase polymerase chain reaction in lymph nodes of node-negative colorectal cancer patients. J Clin Oncol. 2002;20:1049–1055.PubMedCrossRefGoogle Scholar
  43. 43.
    Mellado B, Del Carmen Vela M, Colomer D, et al. Tyrosinase mRNA in blood of patients with melanoma treated with adjuvant interferon. Clin Oncol. 2002;20:4032–4039.CrossRefGoogle Scholar
  44. 44.
    Kuo CT, Hoon DS, Takeuchi H, et al. Prediction of disease outcome in melanoma patients by molecular analysis of paraffin-embedded sentinel lymph nodes. J Clin Oncol. 2003;21:3566–3572.PubMedCrossRefGoogle Scholar
  45. 45.
    Uchikura K, Takao S, Nakajo A, et al. Intraoperative molecular detection of circulating tumor cells by reverse transcription-polymerase chain reaction in patients with biliary-pancreatic cancer is associated with hematogenous metastasis. Ann Surg Oncol. 2002;9:364–370.PubMedCrossRefGoogle Scholar
  46. 46.
    Bessho A, Tabata M, Kiura K, et al. Detection of occult tumor cells in peripheral blood from patients with small cell lung cancer by reverse transcriptase-polymerase chain reaction. Anticancer Res. 2000;20:1149–1154.PubMedGoogle Scholar
  47. 47.
    Brown HM, Ahrendt SA, Komorowski RA, Doffek KM, Wilson SD, Demeure MJ. Immunohistochemistry and molecular detection of nodal micrometastases in pancreatic cancer. J Surg Res. 2001;95:141–146.PubMedCrossRefGoogle Scholar
  48. 48.
    Godfrey TE, Kim S-H, Chavira M, et al. Quantitative mRNA expression analysis from formalin-fixed, paraffin-embedded tissues using 5? nuclease quantitative reverse transcription-polymerase chain reaction. J Mol Diagn. 2000;2:84–91.PubMedGoogle Scholar
  49. 49.
    International (Ludwig) Breast Cancer Study Group. Prognostic importance of occult axillary lymph node micrometastases from breast cancer. Lancet. 1990;335:1565–1568.Google Scholar
  50. 50.
    Keene SA, Demeure MJ. The clinical significance of micrometastases and molecular metastases. Surgery. 2001;129:1–5.PubMedCrossRefGoogle Scholar
  51. 51.
    Raja S, Luketich JD, Kelly LA, Gooding WE, Finkelstein SD, Godfrey TE. Rapid, quantitative reverse transcriptase-polymerase chain reaction: application to intraoperative molecular detection of occult metastases in esophageal cancer. J Thorac Cardiovasc Surg. 2002;123:475–483.PubMedCrossRefGoogle Scholar
  52. 52.
    Olsson CA, de Vries GM, Benson MC, et al. The use of RT-PCR for prostate-specific antigen assay to predict potential surgical failures before radical prostatectomy: molecular staging of prostate cancer. Br J Urol. 1996;77:411–417.PubMedGoogle Scholar
  53. 53.
    Hoon DS, Wang Y, Dale PS, et al. Detection of occult melanoma cells in blood with a multiple marker polymerase chain reaction assay. J Clin Oncol. 1995;13:2109–2116.PubMedGoogle Scholar
  54. 54.
    Theodorescu D, Frierson HF, Sikes RA. Molecular determination of surgical margins using fossa biopsies at radical prostatectomy. J Urol. 1999;161:1442–1448.PubMedCrossRefGoogle Scholar
  55. 55.
    Straub B, Müller M, Krause H, et al. Reverse transcriptase-polymerase chain reaction for prostate-specific antigen in the molecular staging of pelvic surgical margins after radical prostatectomy. Urology. 2001;57:1006–1011.PubMedCrossRefGoogle Scholar
  56. 56.
    Guller U, Zajac P, Schnider A, et al. Disseminated single tumor cells as detected by real-time quantitative polymerase chain reaction represent a prognostic factor in patients undergoing surgery for colorectal cancer. Ann Surg. 2002;236:768–776.PubMedCrossRefGoogle Scholar
  57. 57.
    Saito T, Kobayashi M, Harada R, Uemura Y, Taguchi H. Sensitive detection of small cell lung carcinoma cells by reverse transcriptase polymerase chain reaction for prepro-gastrin-releasing peptide mRNA. Cancer. 2003;97:2504–2511.PubMedCrossRefGoogle Scholar
  58. 58.
    Lacroix J, Becker HD, Woerner SM, Rittgen W, Drings P, von Knebel Doeberitz M. Sensitive detection of rare cancer cells in sputum and peripheral blood samples of patients with lung cancer by prepro-GRP-specific RT-PCR. Int J Cancer. 2001;92:1–8.PubMedCrossRefGoogle Scholar
  59. 59.
    Schulze R, Schulze M, Wischnik A, et al. Tumor cell contamination of peripheral blood stem cell transplants and bone marrow in high-risk breast cancer patients. Bone Marrow Transplant. 1997;19:1223–1228.PubMedCrossRefGoogle Scholar
  60. 60.
    Cooper BW, Moss TJ, Ross AA, Ybanez J, Lazarus M. Occult tumor contamination of hematopoietic stem cell products does not affect clinical outcome of autologous transplantation in patients with breast cancer. J Clin Oncol. 1998;16:3509–3517.PubMedGoogle Scholar
  61. 61.
    Smith B, Selby P, Southgate J, Pittman K, Bradley C, Blair GE. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet. 1991;338:1227–1229.PubMedCrossRefGoogle Scholar
  62. 62.
    Hermanek P, Sobin LH, eds. UICC TNM Classification of Malignant Tumors. 5th ed. Berlin: Springer; 1998.Google Scholar
  63. 63.
    Martin KJ, Graner E, Li Y, et al. High-sensitivity array analysis of gene expression for the early detection of disseminated breast tumor cells in peripheral blood. Proc Natl Acad Sci U S A. 2001;98:2646–2651.PubMedCrossRefGoogle Scholar
  64. 64.
    Bosma AJ, Weigelt B, Lambrechts AC, et al. Detection of circulating breast tumor cells by differential expression of marker genes. Clin Cancer Res. 2002;8:1871–1877.PubMedGoogle Scholar
  65. 65.
    Uciechowski P, Eder C, Bökmann B, et al. Prognostic value of genomic alterations in minimal residual cancer cells purified from the blood of breast cancer patients. Br J Cancer. 2000;83:1664–1673.PubMedCrossRefGoogle Scholar
  66. 66.
    Bianco FJ Jr, Wood DP Jr, Gomes de Oliveira J, Nemeth JA, Beaman AA, Cher ML. Proliferation of prostate cancer cells in the bone marrow predicts recurrence in patients with localized prostate cancer. Prostate. 201;49:235–242.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Karen L. Kaul
    • 1
    • 2
  1. 1.Northwestern University Feinberg School of MedicineEvanston
  2. 2.Department of Pathology and Laboratory MedicineEvanston Northwestern HealthcareEvanstonUSA

Personalised recommendations